

## **CHLOROQUINE PHOSPHATE- chloroquine phosphate tablet AvKARE**

-----


### **Chloroquine Phosphate Tablets, USP (500 mg) Rx only**

#### **DESCRIPTION**

Chloroquine phosphate tablet, USP, is a 4-aminoquinoline compound for oral administration. It is a white, crystalline powder, freely soluble in water, practically insoluble in alcohol (ethanol 96%), in chloroform and in ether.

Chloroquine phosphate tablet is an antimalarial and amebicidal drug.

Chemically, it is 7-chloro-4-[[4- (diethylamino)-1-methylbutyl]amino] quinoline phosphate (1:2) and has the following structural formula:



Each tablet contains 500 mg of chloroquine phosphate USP, equivalent to 300 mg chloroquine base.

*Inactive Ingredients:* Anhydrous citric acid, hydrogenated vegetable oil, lactose monohydrate, magnesium stearate, corn starch, pregelatinized starch and starch.

#### **CLINICAL PHARMACOLOGY**

Chloroquine is rapidly and almost completely absorbed from the gastrointestinal tract, and only a small proportion of the administered dose is found in the stools.

Approximately 55% of the drug in the plasma is bound to nondiffusible plasma constituents. Excretion of chloroquine is quite slow but is increased by acidification of the urine. Chloroquine is deposited in the tissues in considerable amounts. In animals, from 200 to 700 times the plasma concentration may be found in the liver, spleen, kidney, and lung; leukocytes also concentrate the drug. The brain and spinal cord, in contrast, contain only 10 to 30 times the amount present in plasma.

Chloroquine undergoes appreciable degradation in the body. The main metabolite is desethylchloroquine, which accounts for one fourth of the total material appearing in the urine; bisdesethylchloroquine, a carboxylic acid derivative, and other metabolic products as yet uncharacterized are found in small amounts. Slightly more than half of the urinary

drug products can be accounted for as unchanged chloroquine.

## Cardiac Electrophysiology

QTc interval prolongation was studied in a randomized, placebo-controlled parallel trial in 116 healthy subjects who received either chloroquine (1,000 mg) alone or in combination with oral azithromycin (500 mg, 1,000 mg, and 1,500 mg once daily). Co-administration of azithromycin increased the QTc interval in a dose- and concentration-dependent manner. In comparison to chloroquine alone, the maximum mean (95% upper confidence bound) increases in QTcF were 5 ms, 7 (12) ms and 9 (14) ms with the co-administration of 500 mg, 1,000 mg and 1,500 mg azithromycin, respectively.

## Microbiology

**Mechanism of Action:** Chloroquine, a 4-aminoquinoline, is an anti-protozoal agent. The precise mechanism by which chloroquine exhibits activity is not known. Chloroquine, may exert its effect against *Plasmodium* species by concentrating in the acid vesicles of the parasite and by inhibiting polymerization of heme. It can also inhibit certain enzymes by its interaction with DNA.

**Activity *in Vitro* and in Clinical Infections:** Chloroquine is active against the erythrocytic forms of susceptible strains of *Plasmodium falciparum*, *Plasmodium malariae*, *Plasmodium ovale*, and *Plasmodium vivax*. Chloroquine is not active against the gametocytes and the exoerythrocytic forms including the hypnozoite stage (*P. vivax* and *P. ovale*) of the *Plasmodium* parasites.

***In vitro* studies with Chloroquine** demonstrated that it is active against the trophozoites of *Entamoeba histolytica*.

**Drug Resistance:** Resistance of *Plasmodium* parasites to chloroquine is widespread (see **INDICATIONS AND USAGE, Limitations of Use in Malaria** and **WARNINGS**).

*Plasmodium* parasites exhibiting reduced susceptibility to hydroxychloroquine also show reduced susceptibility to chloroquine.

Patients in whom chloroquine or hydroxychloroquine have failed to prevent or cure clinical malaria or parasitemia, or patients who acquired malaria in a geographic area where chloroquine resistance is known to occur should be treated with another form of antimalarial therapy (see **WARNINGS** and **INDICATIONS AND USAGE, Limitations of Use**).

## INDICATIONS AND USAGE

Chloroquine phosphate tablets are indicated for the:

- Treatment of uncomplicated malaria due to susceptible strains of *P. falciparum*, *P. malariae*, *P. ovale*, and *P. vivax*.
- Prophylaxis of malaria in geographic areas where resistance to chloroquine is not present.
- Treatment of extraintestinal amebiasis.

Chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites.

Limitations of Use in Malaria:

- Do not use chloroquine phosphate tablets for the treatment of complicated malaria (high-grade parasitemia and/or complications e.g., cerebral malaria or acute renal failure).
- Do not use chloroquine phosphate tablets for malaria prophylaxis in areas where chloroquine resistance occurs, Resistance to chloroquine phosphate tablets are widespread in *P. falciparum*, and is reported in *P. vivax* (see **WARNINGS**).
- Concomitant therapy with an 8-aminoquinoline drug is necessary for treatment of the hypnozoite liver stage forms of *P. vivax* and *P. ovale* (see **DOSAGE AND ADMINISTRATION**).

## CONTRAINDICATIONS

Use of chloroquine phosphate tablets for indications other than acute malaria is contraindicated in the presence of retinal or visual field changes of any etiology.

Use of chloroquine phosphate tablets are contraindicated in patients with known hypersensitivity to 4-aminoquinoline compounds.

## WARNINGS

### Chloroquine-Resistant Malaria

Chloroquine phosphate tablets are not effective against chloroquine- or hydroxychloroquine-resistant strains of *Plasmodium* species (see **CLINICAL PHARMACOLOGY, Microbiology**). Chloroquine resistance is widespread in *P. falciparum* and is reported in *P. vivax*. Before using chloroquine for prophylaxis, it should be ascertained whether chloroquine is appropriate for use in the region to be visited by the traveler. Information regarding the geographic areas where resistance to chloroquine occurs, is available at the Centers for Disease Control and Prevention ([www.cdc.gov/malaria](http://www.cdc.gov/malaria)).

Patients infected with a resistant strain of plasmodia as shown by the fact that normally adequate doses have failed to prevent or cure clinical malaria or parasitemia should be treated with another form of antimalarial therapy.

### Treatment of Exo-Erythrocytic Forms of Malaria

Chloroquine does not treat the hypnozoite liver stage forms of *Plasmodium* and will therefore not prevent relapses of malaria due to *P. vivax* or *P. ovale*. Additional treatment with an anti-malarial agent active against these forms, such as an 8-aminoquinoline, is required for the treatment of infections with *P. vivax* and *P. ovale*.

### Cardiac Effects including Cardiomyopathy and QT prolongation

Fatal and life-threatening cardiotoxicity, including cardiomyopathy and arrhythmias, have been reported with the use of chloroquine (see **ADVERSE REACTIONS** and **OVERDOSAGE**). In multiple cases, endomyocardial biopsy showed association of the cardiomyopathy with phospholipidosis in the absence of inflammation, infiltration, or necrosis. Patients may present with ventricular hypertrophy and conduction disorders. ECG findings include atrioventricular, right or left bundle branch block. Chronic toxicity should be considered when conduction disorders (bundle branch block / atrio-

ventricular heart block) are diagnosed.

QT interval prolongation, torsades de pointes, and ventricular arrhythmias have been reported with the use of chloroquine. The risk is greater if chloroquine is administered at high doses. Chloroquine should be used with caution in patients with cardiac disease, a history of ventricular arrhythmias, uncorrected hypokalemia and/or hypomagnesemia, or bradycardia (< 50 bpm), and during concomitant administration with QT interval prolonging agents due to potential for QT interval prolongation (see **WARNINGS, PRECAUTIONS, Drug Interactions, ADVERSE REACTIONS** and **OVERDOSAGE**). Monitor for signs and symptoms of cardiotoxicity during chloroquine therapy. Discontinue chloroquine if cardiotoxicity is suspected or demonstrated by tissue biopsy.

### **Hypoglycemia**

Chloroquine has been shown to cause severe hypoglycemia including loss of consciousness that could be life-threatening in patients treated with or without antidiabetic medications (see **PRECAUTIONS, Drug Interactions**). Patients treated with chloroquine phosphate tablets should be warned about the risk of hypoglycemia and the associated clinical signs and symptoms. Patients presenting with clinical symptoms suggestive of hypoglycemia during treatment with chloroquine should have their blood glucose level checked and treatment reviewed as necessary.

### **Retinopathy <sup>1</sup>**

Irreversible retinal damage has been observed in some patients who had received chloroquine. Significant risk factors for retinal damage include daily doses of chloroquine phosphate greater than 2.3 mg/kg of actual body weight, durations of use greater than five years, subnormal glomerular filtration, use of some concomitant drug products such as tamoxifen citrate (see **PRECAUTIONS**), and concurrent macular disease.

A baseline ophthalmological examination should be performed within the first year of starting chloroquine phosphate tablets. The baseline exam should include: best corrected distance visual acuity (BCVA), an automated threshold visual field (VF) of the central 10 degrees (with retesting if an abnormality is noted), and spectral domain optical coherence tomography (SD-OCT).

For individuals with significant risk factors (daily dose of chloroquine phosphate greater than 2.3 mg/kg of actual body weight, subnormal glomerular filtration, use of tamoxifen citrate or concurrent macular disease) monitoring should include annual examinations which include BCVA, VF and SD-OCT. For individuals without significant risk factors, annual exams (including BCVA, VF and SD-OCT) can usually be deferred until five years of treatment.

In individuals of Asian descent, retinal toxicity may first be noticed outside the macula. In patients of Asian descent, it is recommended that visual field testing be performed in the central 24 degrees instead of the central 10 degrees.

It is recommended that chloroquine be discontinued if ocular toxicity is suspected and the patient should be closely observed given that retinal changes (and visual disturbances) may progress even after cessation of therapy.

### **Central Nervous System Effects**

Acute extrapyramidal disorders may occur with chloroquine (see **PRECAUTIONS,**

**ADVERSE REACTIONS** and **OVERDOSAGE**). These adverse reactions usually resolve after treatment discontinuation and/or symptomatic treatment.

### **Skeletal Muscle Myopathy and Neuropathy**

Skeletal muscle myopathy or neuropathy leading to progressive weakness and atrophy of proximal muscle groups, and abnormal nerve conduction, have been reported. Muscle and nerve biopsies have shown associated phospholipidosis. Assess muscle strength and deep tendon reflexes periodically in patients on long-term therapy with chloroquine. Discontinue chloroquine if muscle or nerve toxicity is suspected or demonstrated by tissue biopsy.

### **Renal Toxicity**

Proteinuria with or without a moderate reduction in glomerular filtration rate have been reported with the use of chloroquine. Renal biopsy showed phospholipidosis without immune deposits, inflammation, and/or increased cellularity. Physicians should consider phospholipidosis as a possible cause of renal injury in patients with underlying connective tissue disorders who are receiving chloroquine. Discontinue chloroquine if renal toxicity is suspected or demonstrated by tissue biopsy.

### **Pediatric Accidental Ingestion**

A number of fatalities have been reported following the accidental ingestion of chloroquine, sometimes in relatively small doses (0.75 g or 1 g chloroquine phosphate in one 3-year-old child). Patients should be strongly warned to keep chloroquine phosphate tablets out of the reach of children because they are especially sensitive to the 4-aminoquinoline compounds (see **OVERDOSAGE** and **ADVERSE REACTIONS**).

### **Worsening of Psoriasis and Porphyria**

Use of chloroquine phosphate tablets in patients with psoriasis may precipitate a severe attack of psoriasis. When used in patients with porphyria the condition may be exacerbated. Chloroquine phosphate tablets should not be used in these conditions unless the benefit to the patient outweighs the potential risks.

### **Potential Carcinogenic Risk**

Experimental data showed a potential risk of inducing gene mutations. There is insufficient evidence regarding the carcinogenicity of chloroquine in experimental animals (see **PRECAUTIONS, Carcinogenesis, Mutagenesis, Impairment of Fertility**). In humans, there are insufficient data to rule out an increased risk of cancer in patients receiving long-term treatment.

### **Usage in Pregnancy**

In animal studies, embryo-fetal developmental toxicity was shown at doses ranging from 250 mg/kg to 1,500 mg/kg body weight; approximately 3 to 16 times the maximum recommended therapeutic dose based on a body surface area comparison (see **PRECAUTIONS, Animal Pharmacology and/or Animal Toxicology**). Preclinical data showed a potential risk of genotoxicity in some test systems ( **PRECAUTIONS, Carcinogenesis, Mutagenesis, Impairment of Fertility**).

In humans, at recommended doses for prophylaxis and treatment of malaria, observational studies as well as a meta-analysis, including a small number of prospective studies with chloroquine exposure during pregnancy, have shown no increase in the rate of birth defects or spontaneous abortions.

The individual benefit-risk balance should be reviewed before prescribing chloroquine in pregnant women.

## **PRECAUTIONS**

### **Hematological Effects/Laboratory Tests**

Complete blood cell counts should be checked periodically if patients are given prolonged therapy (see **ADVERSE REACTIONS**).

Chloroquine may cause hemolysis in glucose-6 phosphate dehydrogenase (G-6-PD) deficiency. Blood monitoring may be needed as hemolytic anemia may occur, in particular in association with other drugs that cause hemolysis (see **ADVERSE REACTIONS**).

### **Auditory Effects**

In patients with preexisting auditory damage, chloroquine should be administered with caution. In case of any defects in hearing, chloroquine should be immediately discontinued, and the patient closely observed (see **ADVERSE REACTIONS**).

### **Use in Patients with Hepatic Impairment**

Since chloroquine phosphate tablets are known to concentrate in the liver, it should be used with caution in patients with hepatic disease or alcoholism or in conjunction with known hepatotoxic drugs.

### **Central Nervous System Effects**

Chloroquine may increase the risk of convulsions in patients with a history of epilepsy.

### **Drug Interactions**

Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine; an interval of at least 4 hours between intake of these agents and chloroquine should be observed.

Cimetidine: Cimetidine can inhibit the metabolism of chloroquine, increasing its plasma level. Concomitant use of cimetidine should be avoided.

Insulin and other antidiabetic drugs: As chloroquine may enhance the effects of a hypoglycemic treatment, a decrease in doses of insulin or other antidiabetic drugs may be required.

Arrhythmogenic drugs: There may be an increased risk of inducing ventricular arrhythmias if chloroquine is used concomitantly with other arrhythmogenic drugs, such as amiodarone or moxifloxacin.

Ampicillin: In a study of healthy volunteers, chloroquine significantly reduced the

bioavailability of ampicillin. An interval of at least two hours between intake of ampicillin and chloroquine should be observed.

Cyclosporine: After introduction of chloroquine (oral form), a sudden increase in serum cyclosporine level has been reported. Therefore, close monitoring of serum cyclosporine level is recommended and, if necessary, chloroquine should be discontinued.

Mefloquine: Co-administration of chloroquine and mefloquine may increase the risk of convulsions.

The blood concentrations of chloroquine and desethylchloroquine (the major metabolite of chloroquine, which also has antimalarial properties) were negatively associated with log antibody titers. Chloroquine taken in the dose recommended for malaria prophylaxis can reduce the antibody response to primary immunization with intradermal human diploid-cell rabies vaccine.

Praziquantel: In a single-dose interaction study, chloroquine has been reported to reduce the bioavailability of praziquantel.

Tamoxifen: Concomitant use of chloroquine with drugs known to induce retinal toxicity such as tamoxifen is not recommended (see WARNINGS).

## **Carcinogenesis, Mutagenesis, Impairment of Fertility**

### **Carcinogenesis**

There is insufficient evidence regarding the carcinogenicity of chloroquine in experimental animals.

### **Mutagenesis**

Chloroquine is reported in the literature to be a weak genotoxic agent which may elicit both gene mutations and chromosomal/DNA breaks. Mechanisms may involve DNA intercalation or induction of oxidative stress. The publications reported both positive and negative results in the *in vitro* reverse gene mutation assays using bacteria (Ames test) and in the *in vivo* studies using rodents (mouse bone marrow cell sister chromatid exchange, mouse bone marrow cell chromosome abnormality, and rat DNA strand breaks in multiple organs when animals were dosed by intraperitoneal route). Those chromosomal effects were not observed when chloroquine was administered in animals orally (i.e. the therapeutic route of administration). Altogether those cellular and rodent data show evidence of genotoxic potential but discrepancies have been noted between published data.

### **Fertility**

A study in male rats after 30 days of oral treatment at 5 mg/day of chloroquine showed a decrease in testosterone levels, weight of testes, epididymis, seminal vesicles, and prostate. Untreated female rats had reduced number of fetuses after mating with males that received intraperitoneal injections of 10 mg/kg chloroquine for 14 days.

## **Animal Pharmacology and/or Animal Toxicology**

Based on non-Good Laboratory Practice literature reports, chloroquine causes malformations in rats, resulting in a fetal mortality rate of 25% after administration at doses between 250 mg/kg and 1,500 mg/kg (approximately 3 to 16 times the maximum recommended therapeutic dose of 900 mg of chloroquine base, based on a body

surface area comparison), showing ocular malformations in 45% of fetuses in the 1,000 mg/kg group (approximately 11 times the maximum recommended therapeutic dose based on a body surface area comparison). Autoradiographic studies have shown that when administered at the start or the end of gestation, chloroquine accumulates in the eyes and ears.

## **Pregnancy**

See **WARNINGS, Usage in Pregnancy.**

## **Nursing Mothers**

Because of the potential for serious adverse reactions in nursing infants from chloroquine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the potential clinical benefit of the drug to the mother.

The excretion of chloroquine and the major metabolite, desethylchloroquine, in breast milk was investigated in eleven lactating mothers following a single oral dose of chloroquine (600 mg base). The maximum daily dose of the drug that the infant can receive from breastfeeding was about 0.7% of the maternal start dose of the drug in malaria chemotherapy. Separate chemoprophylaxis for the infant is required (see **DOSAGE AND ADMINISTRATION**).

## **Pediatric Use**

See **WARNINGS** and **DOSAGE AND ADMINISTRATION**.

## **Geriatric Use**

Clinical studies of chloroquine phosphate tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, this drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function.

## **ADVERSE REACTIONS**

The following adverse reactions have been identified during post-approval use of chloroquine or other 4-aminoquinoline compounds. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

**Ocular disorders:** Maculopathy and macular degeneration have been reported and may be irreversible. Irreversible retinopathy with retinal pigmentation changes (bull's eye appearance) and visual field defects (paracentral scotomas) in patients receiving long-term or high-dosage 4- aminoquinoline therapy have been reported (see **WARNINGS**). Visual disturbances (blurring of vision and difficulty of focusing or accommodation); nyctalopia; scotomatous vision with field defects of paracentral, pericentral ring types, and typically temporal scotomas (e.g., difficulty in reading with words tending to disappear, seeing half an object, misty vision, and fog before the eyes) have been



reported. Reversible corneal opacities have also been reported.

**Immune system disorders:**Urticaria, anaphylactic reaction including angioedema.

**Ear and labyrinth disorders:**Nerve type deafness; tinnitus, reduced hearing in patients with preexisting auditory damage.

**Musculoskeletal and connective tissue-disorders:**Sensorimotor disorders, skeletal muscle myopathy or neuromyopathy leading to progressive weakness and atrophy of proximal muscle groups, depression of tendon reflexes and abnormal nerve conduction.

**Gastrointestinal disorders:**Hepatitis, increased liver enzymes, anorexia, nausea, vomiting, diarrhea, abdominal cramps.

**Skin and subcutaneous tissue disorders:**Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis. Pleomorphic skin eruptions, skin and mucosal pigmentary changes; lichen planus-like eruptions, pruritus,; drug rash with eosinophilia and systemic symptoms (DRESS syndrome); photosensitivity and hair loss and bleaching of hair pigment.

**Blood and lymphatic system disorders:**Pancytopenia, aplastic anemia, reversible agranulocytosis, thrombocytopenia and neutropenia. Hemolytic anemia in G6PD deficient patients (see **PRECAUTIONS**).

**Nervous system disorders:**Convulsions, mild and transient headache, polyneuropathy, acute extrapyramidal disorders (such as dystonia, dyskinesia, tongue protrusion, torticollis) (see **WARNINGS** and **OVERDOSAGE**).

**Neuropsychiatric disorders:**Neuropsychiatric changes including psychosis, delirium, anxiety, agitation, insomnia, confusion, hallucinations, personality changes, depression, and suicidal behavior.

**Cardiac disorders:**Hypotension, electrocardiographic changes (particularly, inversion or depression of the T-wave with widening of the QRS complex), and cardiomyopathy (which may result in cardiac failure and in some cases a fatal outcome).

Cardiac arrhythmias, conduction disorders such as bundle branch block / atrio-ventricular block, QT interval prolongation, torsade de pointes, ventricular tachycardia and ventricular fibrillation have been reported with therapeutic doses of chloroquine as well as with overdose. The risk is greater if chloroquine is administered at high doses. Fatal cases have been reported (see **WARNINGS, Cardiac Effects** and **OVERDOSAGE**).

**Metabolic and Nutritional disorders:**Hypoglycemia (see **WARNINGS**).

**To report SUSPECTED ADVERSE REACTIONS, contact AvKARE at 1-855-361-3993 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

## **OVERDOSAGE**

**Signs and Symptoms:**Chloroquine is very rapidly and completely absorbed after ingestion. Toxic doses of chloroquine can be fatal. As little as 1 g may be fatal in children. Toxic symptoms can occur within minutes. The symptoms of overdose may include nausea, vomiting, headache, drowsiness, visual disturbances, cardiovascular

collapse, convulsions, hypokalemia, rhythm and conduction disorders including QT prolongation, torsades de pointes, ventricular tachycardia and ventricular fibrillation, followed by sudden potentially fatal respiratory and cardiac arrest. Immediate medical attention is required, as these effects may appear shortly after the overdose. Cases of extrapyramidal disorders have also been reported in the context of chloroquine overdose (see **WARNINGS** and **ADVERSE REACTIONS**).

**Treatment:** Treatment is symptomatic and must be prompt with immediate evacuation of the stomach by emesis or gastric lavage followed by treatment with activated charcoal. Chloroquine overdose is a life-threatening emergency and should be managed with cardio-respiratory and hemodynamic support, monitoring of potassium along with management of arrhythmias and convulsions, as necessary. A patient who survives the acute phase and is asymptomatic should be closely observed until all clinical features of toxicity resolve.

## **DOSAGE AND ADMINISTRATION**

The dosage of chloroquine phosphate is often expressed in terms of equivalent chloroquine base. Each 500 mg tablet of chloroquine phosphate tablet contains the equivalent of 300 mg chloroquine base. In infants and children the dosage is preferably calculated by body weight.

### **Prophylaxis against chloroquine-sensitive *Plasmodium* species**

**Adult Dose:** The dosage for prophylaxis is 500 mg (= 300 mg base) administered once per week on exactly the same day of each week.

**Pediatric Dose:** The dosage for prophylaxis is 5 mg calculated as base, per kg of body weight, administered once per week on exactly the same day of each week. The pediatric dose should never exceed the adult dose regardless of weight.

If circumstances permit, suppressive therapy should begin two weeks prior to exposure. However, failing this in adults, an initial double (loading) dose of 1 g (= 600 mg base), or in children 10 mg base/kg may be taken in two divided doses, six hours apart. The suppressive therapy should be continued for eight weeks after leaving the endemic area.

### **Treatment of uncomplicated malaria due to chloroquine-sensitive *Plasmodium* species**

**Adults:** An initial dose of 1 g salt (= 600 mg base) followed by an additional 500 mg (= 300 mg base) after six to eight hours and a single dose of 500 mg (= 300 mg base) on each of two consecutive days. This represents a total dose of 2.5 g chloroquine phosphate or 1.5 g base in three days.

**Infants and Children:** In infants and children, the recommended dose is 10 mg base/kg followed by 5 mg based/kg at 6, 24 and 36 hours (total dose 25 mg based/kg). The pediatric dose should never exceed the adult dose regardless of weight.

The dosage for adults of low body weight and for infants and children should be determined as follows:

First dose: 10 mg base per kg (but not exceeding a single dose of 600 mg base).

Second dose: (6 hours after first dose) 5 mg base per kg (but not exceeding a single

dose of 300 mg base).

Third dose: (24 hours after first dose) 5 mg base per kg.

Fourth dose: (36 hours after first dose) 5 mg base per kg.

***P. vivax* and *P. ovale*:** Concomitant therapy with an 8-aminoquinoline compound is necessary for treatment of the hypnozoite liver stage forms of the parasites.

**Extraintestinal Amebiasis: Adults Dosage:** 1 g salt (600 mg base) daily for two days, followed by 500 mg (300 mg base) daily for at least two to three weeks. Treatment is usually combined with an effective intestinal amebicide.

### **Geriatric Use**

See **PRECAUTIONS, Geriatric Use.**

### **HOW SUPPLIED**

Chloroquine Phosphate Tablets USP, **500 mg**, equivalent to 300 mg of chloroquine base are supplied as white to off-white, round tablets, debossed with "7010" on one side and plain on the other side.

They are available as follows:

Bottles of 25: NDC 42291-047-25

Dispense in tight, light-resistant container as defined in the USP.

Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]

### **REFERENCES**

1. Marmor MF, Kellner U, and Lai TY, et al. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). *Ophthalmology* 2016. Doi10.1016/j.jophtha.2016.01.058

Manufactured for:

AvKARE

Pulaski, TN 38478

Mfg. Rev. 05-2022-01

AV 11/23 (M)

### **PRINCIPAL DISPLAY PANEL**



**Chloroquine Phosphate Tablets, USP**

**500 mg\***

For use in Malaria and Extraintestinal Amebiasis Only

**25 Tablets Rx Only**

\*Each tablet contains: Chloroquine Phosphate, USP ..... 500 mg (Equivalent to 300 mg Chloroquine base)  
**Usual Dosage:** See accompanying Prescribing Information.

**Store at 20° to 25° C (68° to 77° F); excursions permitted between 15° to 25° C (59° to 88° F) [see USP Controlled Room Temperature].**

Dispense in light, light-resistant container as defined in the USP.

Keep this and all drugs out of the reach of children.

Manufactured for:

**AVKARE**  
 P.O. Box 38478  
 Memphis, TN 38178

www.avkare.com

Mfg. Rev. 04-2002-00 AV 11/23 (W)



## CHLOROQUINE PHOSPHATE

chloroquine phosphate tablet

### Product Information

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:42291-047(NDC:0115-7010)
<b>Route of Administration</b>	ORAL		

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
<b>CHLOROQUINE PHOSPHATE</b> (UNII: 6E17K3343P) (CHLOROQUINE - UNII:886U3H6UFF)	CHLOROQUINE PHOSPHATE	500 mg

### Inactive Ingredients

Ingredient Name	Strength
<b>ANHYDROUS CITRIC ACID</b> (UNII: XF417D3PSL)	
<b>HYDROGENATED COTTONSEED OIL</b> (UNII: Z82Y2C65EA)	
<b>LACTOSE MONOHYDRATE</b> (UNII: EWQ57Q8I5X)	
<b>MAGNESIUM STEARATE</b> (UNII: 70097M6I30)	
<b>STARCH, CORN</b> (UNII: O8232NY3S)	
<b>STARCH, POTATO</b> (UNII: 8I089SAH3T)	

### Product Characteristics

<b>Color</b>	white (white to off-white)	<b>Score</b>	no score
<b>Shape</b>	ROUND	<b>Size</b>	13mm
<b>Flavor</b>		<b>Imprint Code</b>	7010
<b>Contains</b>			

### Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:42291-047-25	25 in 1 BOTTLE; Type 0: Not a Combination Product	11/15/2023	

## Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA040516	11/15/2023	

**Labeler** - AvKARE (796560394)

Revised: 11/2023

AvKARE